Based upon our findings and limitation of the study, research should experimentally validate the proposed DHRS4-AS1/hsa-miR-222-3p/TMBIM6 axis through in vitro binding assays, functional knockdown/overexpression studies, and in vivo prostate cancer models to confirm its mechanistic role. This evidence concerns the gene TMBIM6 and prostate carcinoma.